Vera Therapeutics Inc. (VERA)
Vera Therapeutics Inc. (VERA) Stock Price, Analysis & Data
| Bid | 22.14 |
| Market Cap | 2.22B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -401.9M |
| Beta | 0.95 |
| EPS (ttm) | -5.87 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.4 |
| P/B (ttm) | 5.44 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 38.91 |
| Volume | 270,543 |
| Avg. Volume (20D) | 1,858,522 |
| Open | 30.75 |
| Previous Close | 30.29 |
| Day's Range | 30.27 - 31.18 |
| 52-Week Range | 21.04 - 56.05 |
| Analyst | Strong Buy |
| Price Target | 85 (175.71%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immuno...
Financial Performance
In 2025, Vera Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -299.62M, an increase of 96.92%.
Financial StatementsAnalyst Forecast
According to 14 analyst ratings, the average rating for VERA stock is "Strong Buy". The 12-month stock price forecast is 85, which is upside of 175.71% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
